2015
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. The Journal Of Infectious Diseases 2015, 213: 1523-1531. PMID: 26681778, PMCID: PMC4837902, DOI: 10.1093/infdis/jiv523.Peer-Reviewed Original ResearchConceptsStandard prepSouth African womenPreexposure prophylaxisHIV infectionHigh riskHuman immunodeficiency virus (HIV) infectionEffective prevention optionsAfrican womenImmunodeficiency virus infectionCost-saving interventionHIV infection riskYoung South African womenLikely clinical benefitInjectable PrEPPrEP formulationsEligible womenClinical benefitPotential ClinicalVirus infectionOutcome measuresPrEP strategiesProgram costsPrevention optionsSurvival rateGreater adherence
2013
Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park JE, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, Paltiel AD. Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. PLOS ONE 2013, 8: e84173. PMID: 24367639, PMCID: PMC3867470, DOI: 10.1371/journal.pone.0084173.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioQuality-adjusted life monthsRoutine HIVHIV test acceptanceRoutine HIV screeningAge 43 yearsCells/μLSecondary HIV transmissionHigh-risk groupHigh-risk populationRoutine screening programQuality-adjusted survivalCost-effectiveness ratioCD4 countHIV screeningClinical outcomesHIV prevalenceHIV transmissionFrequent screeningClinical impactNational HIVScreening programHigh incidenceHIV
2011
Medical Device Innovation — Is “Better” Good Enough?
Suter LG, Paltiel AD, Rome BN, Solomon DH, Golovaty I, Gerlovin H, Katz JN, Losina E. Medical Device Innovation — Is “Better” Good Enough? New England Journal Of Medicine 2011, 365: 1464-1466. PMID: 22010911, PMCID: PMC3570242, DOI: 10.1056/nejmp1109285.Peer-Reviewed Original Research
2006
Forced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma
Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD. Forced Expiratory Volume in 1 Second Percentage Improves the Classification of Severity Among Children With Asthma. Pediatrics 2006, 118: e347-e355. PMID: 16864642, DOI: 10.1542/peds.2005-2962.Peer-Reviewed Original ResearchMeSH KeywordsAlbuterolAnti-Asthmatic AgentsAsthmaBronchial Provocation TestsBronchodilator AgentsBudesonideChildChild, PreschoolCohort StudiesDouble-Blind MethodEmergency Service, HospitalEthnicityFemaleFollow-Up StudiesForced Expiratory VolumeHospitalizationHumansMaleMethacholine ChlorideModels, TheoreticalMulticenter Studies as TopicNedocromilRandomized Controlled Trials as TopicRiskSeverity of Illness IndexSpirometryTreatment OutcomeConceptsSerious asthma exacerbationsImportant clinical outcomesHealth care utilizationPrebronchodilator FEV1Asthma exacerbationsAsthma symptomsExpiratory volumeCare utilizationClinical outcomesSecond percentageAsthma health statusAsthma severity classificationAsthma-related eventsChildhood Asthma Management ProgramEpisode-free daysNational Asthma EducationAsthma-related hospitalizationsPrevention Program guidelinesMean symptom scoreAsthma Management ProgramFuture adverse eventsOutcomes of interestMultivariate regression analysisPopulation of childrenClassification of severity